Please login to the form below

Not currently logged in
Email:
Password:

Novel HIV treatment shows promise

Myriad Pharmaceuticals' HIV treatment MPC-4326 "safe and well tolerated"

Myriad Pharmaceuticals' HIV treatment MPC-4326 is safe and well tolerated according to two abstracts presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting on 12–15 September in San Francisco, US.

MPC-4326 is the first 'maturation inhibitor' a new class of HIV drug that inhibits the final step in the processing of the HIV Gag protein. Treatments with novel mechanism of action are though to be critical to combat drug resistance to available HIV therapies.

"I am very excited that the new 100 mg tablet formulation of MPC-4326 has performed so well," said Dr Adrian Hobden, President and CEO of the Salt Lake City-based biopharmaceutical company. "Coupled with the potential companion diagnostic and the significant viral load reductions seen in these two studies, we believe that we have a clear clinical path forward."

15th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics